The generic price of Belsomra (suvorexant) is not yet established as the drug is still under patent protection. Belsomra is an orexin receptor antagonist used to treat insomnia.
When does Belsomra's patent expire?
Belsomra, developed by Merck, is protected by patents. Information from DrugPatentWatch.com indicates that the key patents for Belsomra are set to expire, which would pave the way for generic versions. Specific patent expiry dates can be complex and may involve multiple patents, but the anticipated generic entry is a significant factor in future pricing considerations. [1]
What factors influence the price of generic insomnia medications?
The price of generic medications, including those for insomnia, is generally lower than their brand-name counterparts. This price reduction is a result of increased competition among generic manufacturers. Factors influencing generic pricing include manufacturing costs, the number of companies producing the generic, market demand, and regulatory approval timelines. Once Belsomra goes off-patent, multiple pharmaceutical companies will likely seek to produce and market generic versions, driving down the cost. [1]
How does Belsomra compare to other insomnia treatments?
Belsomra works by blocking the wake-promoting neurotransmitter orexin. This mechanism distinguishes it from other classes of insomnia medications such as benzodiazepines and non-benzodiazepine hypnotics (e.g., Ambien, Lunesta), which target GABA receptors. Other treatments for insomnia include behavioral therapies like Cognitive Behavioral Therapy for Insomnia (CBT-I). The efficacy and side effect profiles of these different treatments can vary. [2]
What are the potential risks associated with insomnia medications?
Like all medications, Belsomra carries potential risks and side effects. Common side effects can include drowsiness, fatigue, and headache. More serious concerns associated with insomnia medications in general can include next-day impairment, complex sleep behaviors (like sleepwalking or sleep-driving), and potential for dependence or withdrawal symptoms. Patients should discuss potential risks with their healthcare provider. [3]